6515--NX EQ Electrosurgical Units, Argon-Enhanced Coagulation

Active

Contract Opportunity

Combined Synopsis/Solicitation Notice

Combined Synopsis/Solicitation Notice

Page 3 of 14
Combined Synopsis/Solicitation Notice
*= Required Field
Combined Synopsis/Solicitation Notice

Page 1 of 14
Solicitation Number:

36C10X26Q0059

Notice Type:

Combined Synopsis/Solicitation

Synopsis:

COMBINED SYNOPSIS/SOLICITATION

This is a combined synopsis/solicitation for commercial items prepared in accordance with (IAW) the format in Federal Acquisition Regulation (FAR) 12.202, Publicizing, as supplemented with additional information included in this notice. This announcement constitutes the only solicitation; quotes are being requested, and a written solicitation will not be issued.

Solicitation number 36C10X26Q0059 is issued for this combined synopsis/solicitation; this solicitation is being issued as a Request for Quote (RFQ). This combined synopsis/solicitation is issued under the agency's implementation of the Federal Acquisition Regulation (FAR) Overhaul, as adopted through agency class deviation. All applicable provisions, clauses, definitions, and procedures are those contained in the Overhaul text and the agency's implementation deviations. In the event of a conflict with the codified FAR, the adopted Overhaul text governs. The full text of provisions and clauses may be accessed electronically at https://www.acquisition.gov/far-overhaul/far-part-deviation-guide.

Requirement Description:

The Veterans Health Administration (VHA) Non-Expendable (NX) National Program has identified the Erbe® VIO 3, Electrosurgical Units, Argon-Enhanced Coagulation product line as a candidate for an Enterprise-wide (otherwise referred to as national ) single Requirements contract award. Electrosurgical Units (ESUs); Argon-Enhanced Coagulation (AEC) are advanced, energy based surgical systems used to perform precise tissue coagulation and devitalization across Veterans Affairs Medical Centers (VAMCs), particularly in operating rooms (OR), procedural suites, and endoscopy units. They deliver radiofrequency (RF) energy through specialized electrodes while directing a controlled flow of inert argon gas to create a conductive plasma at the tissue surface. This results in uniform, noncontact coagulation with minimal tissue penetration, improved visualization, and reduced bleeding. ESUs with AEC are designed to enhance surgical efficiency, improve hemostasis, and support consistent, replicable outcomes across a range of open, laparoscopic, and endoscopic procedures.

These systems provide real-time, automated control of power delivery, argon flow, and activation mode, with integrated safety monitoring and configurable presets for procedure-specific use. They are optimized to increase clinical efficiency and reduce complications through precision energy delivery, reliable tissue effect profiles, and comprehensive safety interlocks.

A single award Requirements contract will be awarded IAW all terms, conditions, provisions, specifications, and schedule of this solicitation herein. Quotes shall contain the terms for cost/price and technical capabilities of brand name equipment. The Government reserves the right to award without discussions.

The associated North American Industrial Classification System (NAICS) code for this procurement is 339112 Surgical and Medical Instrument Manufacturing, Product Service Code: 6515 Medical and Surgical Instruments, Equipment, and Supplies and the associated size standard is 1,000 employees. This procurement action is issued as Full and Open.

This acquisition is for a single award Requirements contract with firm-fixed priced (FFP) delivery orders IAW FAR Part 16.5 for Brand Name or Equal which requires the offeror indicate that each product being offered as an equal product to the Brand Name Olympus ESG-300 Electrosurgical System.
Offerors shall provide a quote for all Contract Line-Item Numbers (CLINs) listed in ATTACHMENT A - PRICE COST SCHEDULE - NX EQ Electrosurgical Units, Argon-Enhanced Coagulation.

The ordering period is for one 12-month base year with four 12-month option years. Delivery is Free on Board (FOB) destination. FFP Orders will be placed against this contract in writing and will provide the delivery locations, delivery dates and exact quantities.Â
Â
The FAR provision at 52.212-1, Instructions to Offerors-Commercial Products And Commercial Services, applies to this acquisition including attached addenda to the provision (see ATTACHMENT D - SOLICITATION PROVISIONS - NX EQ Electrosurgical Units, Argon-Enhanced Coagulation).

The FAR provision at 52.212-2, Evaluation-Commercial Products and Commercial Services, and the specific evaluation criteria as attached addenda also applies to this acquisition (see ATTACHMENT D - NX EQ Electrosurgical Units, Argon-Enhanced Coagulation).

Clause at 52.212-4, Contract Terms and Conditions-Commercial Products and Commercial Services, applies to this acquisition and a statement regarding any addenda to the clause. (see ATTACHMENT C - CONTRACT CLAUSES NX EQ Electrosurgical Units, Argon-Enhanced Coagulation).

All interested Offerors must be registered in the System for Award Management (SAM) prior to submitting a quote. You may access SAM at https://sam.gov/SAM/.

Questions regarding this combined synopsis/solicitation are due via email by 11:59 PM EST on April 09, 2026, to Contract Specialist (CS) Daleta Coles, Daleta.Coles@va.gov and Contracting Officer (CO) Hosea Berkley, Hosea.Berkley@va.gov. No questions will be accepted after the due date. No calls will be accepted.

Quotes are due via email by 11:59PM EST on April 15, 2026, to Contract Specialist (CS) Daleta Coles, Daleta.Coles@va.gov and Contracting Officer (CO) Hosea Berkley, Hosea.Berkley@va.gov
PRODUCT DESCRIPTION

1. SCOPE OF WORK
The Veterans Health Administration (VHA) Non-Expendable Equipment National Program has identified Electrosurgical Units (ESUs); Argon-Enhanced Coagulation product line as a candidate for a VA-wide (otherwise referred to as national ) single Requirements contract award.

Electrosurgical Units (ESUs); Argon-Enhanced Coagulation (AEC) are advanced, energy based surgical systems used to perform precise tissue coagulation and devitalization across Veterans Affairs Medical Centers (VAMCs), particularly in operating rooms (OR), procedural suites, and endoscopy units. They deliver radiofrequency (RF) energy through specialized electrodes while directing a controlled flow of inert argon gas to create a conductive plasma at the tissue surface. This results in uniform, noncontact coagulation with minimal tissue penetration, improved visualization, and reduced bleeding. ESUs with AEC are designed to enhance surgical efficiency, improve hemostasis, and support consistent, replicable outcomes across a range of open, laparoscopic, and endoscopic procedures.

These systems provide real-time, automated control of power delivery, argon flow, and activation mode, with integrated safety monitoring and configurable presets for procedure-specific use. They are optimized to increase clinical efficiency and reduce complications through precision energy delivery, reliable tissue effect profiles, and comprehensive safety interlocks.

Offerors must demonstrate the ability to meet all requirements for the solicitation. The objective is to provide an Electrosurgical Units (ESUs); Argon Enhanced Coagulation system to be used by clinicians throughout the VA medical centers and facilities. The period of performance is for a 12-month base period and four 12-month option periods.
2. REQUIREMENT
This requirement will be solicited and awarded as a Brand Name or Equal which requires the quoter indicate that each product being offered as an equal product to the Erbe® VIO 3 Electrosurgical Units (ESUs); Argon-Enhanced Coagulation system. For each equal product, the offeror must include a description reflecting the salient characteristics (SC) and level of quality that will satisfy the salient physical, functional, or performance characteristics of the equal product(s) specified in the solicitation. The quoter must also clearly identify the item by brand name (if any) and make/model number. Finally, the quoter must include descriptive literature, such as illustrations, drawings, or a clear reference to previously furnished descriptive data or information available to the Contracting Officer and clearly describe any modifications it plans to make to a product to conform to the solicitation requirements.

The following line-items comprise the Erbe® VIO 3 Electrosurgical Units (ESUs); Argon-Enhanced Coagulation system product line:
Contract Line-Item
Brand
Part Number
Description
0001
ERBE USA Inc.

VIO® 3
0001A
ERBE USA Inc.
10160-000
VIO® Electrosurgical unit
0001B
ERBE USA Inc.
20189-353
Two-pedal foot switch, VIO® 3 ReMode®, bracket, middle piece
0001C
ERBE USA Inc.
20188-350
One-pedal foot switch, VIO® 3 ReMode®
0001D
ERBE USA Inc.
20180-000
VIO® CART System carrier for VIO®
0001E
ERBE USA Inc.
20180-010
Wire basket, 339 x 205 x 155 / 100 mm
0002
ERBE USA Inc.

Attachment Sets
0002A
ERBE USA Inc.
20180-140
Fastening set for VIO® 3 on VIO® Cart
0002B
ERBE USA Inc.
20180-143
Fastening set VIO® 3 for APC® 3 on boom mount
0002C
ERBE USA Inc.
20180-144
Fastening set VIO® 3 for APC® 3 on ERBEJET® 2
0003
ERBE USA Inc.

Instrument cables from Erbe
0003A
ERBE USA Inc.
20192-133
Monopolar cable MO 3Pin; MIS OD 4mm; L 4.5m
0003B
ERBE USA Inc.
20192-134
Monopolar cable MO 3Pin; OD 4.5mm pin; L 4.5m
0003C
ERBE USA Inc.
20192-135
Monopolar cable MO 3Pin; OD 3mm socket; L 4.5m
0003D
ERBE USA Inc.
20196-064
Bipolar cable BI 2Pin28; ang.; forceps; L 4.5m
0003E
ERBE USA Inc.
20196-067
Bipolar cable BI 2Pin28; grasp. forceps; L 4.5m
0003F
ERBE USA Inc.
20196-127
Bipolar cable BI 2Pin28; forceps 2Pin; L 4m
0003G
ERBE USA Inc.
21196-115
Bipolar Connecting Cable; MF-U Olympus Resectoscope; L 4.5m
0003H
ERBE USA Inc.
21196-118
Bipolar Connecting Cable; MF-U Storz Resectoscope; L 4.5m
0003I
ERBE USA Inc.
21196-119
Bipolar Connecting Cable; MF-U Wolf Resectoscope; L 4.5m
0004
ERBE USA Inc.

VIO® 300 D
0004A
ERBE USA Inc.
10140-100
VIO® 300 D Electrosurgical Unit 120V/60HZ UL , Software Version 2.X Constant Voltage
0004B
ERBE USA Inc.
20189-305
VIO® two pedal footswitch w/ReMode® w/Bracket (Remode Feature Allows Changing between Preset Programs)
0004C
ERBE USA Inc.
20180 131
Connection Adapter, Cryo Probe to Erbokryo CA
0004D
ERBE USA Inc.
20183-053
Adapter for BICAP or Gold Probe
0004E
ERBE USA Inc.
20193-084
NESSY® Omega monitoring pad with cable (50 per case)
0004F
ERBE USA Inc.
20180-000
VIO® Cart with footswitch holder, cable wrap and 1 tank fixation kit
0004G
ERBE USA Inc.
20180-010
VIO® Cart wire basket
0004H
ERBE USA Inc.
20180-131
VIO®/APC® 2 to VIO® Cart fastening set (with grounding cable)

The VA is seeking offerors who can provide Erbe® VIO 3 Electrosurgical Units (ESUs); Argon-Enhanced Coagulation system or equal as listed above which meet all the following salient characteristics: Vendors may quote any product solution or configuration so long as they meet the salient characteristics.
Offerors may quote an alternative CLIN structure IAW FAR 4.202-2 and 4.202-3. Products quoted in the technical volume must appear on and correspond with the Offeror s pricing volume (ATTACHMENT A - PRICE COST SCHEDULE - NX EQ Electrosurgical Units, Argon-Enhanced Coagulation).
Offerors may quote any additional ancillary products which they deem to be essential to the functionality of the quoted solution; these ancillary items must be quantified in the Offeror s pricing volume with an estimated quantity of zero (0).
Only new equipment is acceptable; no remanufactured or "gray market" items. No product in development shall be considered. All items must be covered by the manufacturer's warranty.
Distributors must be authorized-distributors/resellers as certified by the Original Equipment Manufacturer (OEM) (i.e., OEM letter dated within 12 months of the solicitation close date and duly signed by OEM s authorized representative) to be eligible for award. The OEM letter must be valid for the life of the contract.

CLIN s 0001 apply to SC s 0001-0004

SC #
SALIENT CHARACTERISTICS
METHOD OF EVALUATION

SC Literature Map
(Brand Name/Page #)
SC 1
Must be cleared by the U.S. Food and Drug Administration (FDA) as an electrosurgical generator with compatible argon-enhanced coagulation capability for cutting and coagulation of tissue in general, laparoscopic, and endoscopic surgery, including hemostasis and devitalization of soft tissues.
Literature Review
SC 2
Must provide a centralized color touchscreen user interface that allows the operator to select, monitor, and adjust at minimum: Electrosurgical mode (e.g., monopolar cut, monopolar coagulation, bipolar, argon coagulation); Output power settings (watts); Application-relevant parameters (e.g., argon gas flow and effect settings for argon-enhanced coagulation); and Treatment or activation time (timer or activation counters).
Literature Review
SC 3
Must be compatible with a range of monopolar and bipolar instruments, as well as compatible argon probes/catheters and applicators, in various working lengths suitable for open and endoscopic procedures.
Literature Review
SC4
Must consist of modular argon plasma capability with adjustable gas flow rates (0.1 to 6 L/min) and multiple APC waveforms (precise, pulsed, forced) for non-contact surface coagulation, enabling effective hemostasis and tissue ablation in gastrointestinal, respiratory, and other anatomical applications.
Literature Review
SC 5
Must have advanced neutral electrode monitoring (such as NESSY technology) that dynamically tracks patient impedance levels and return electrode contact/orientation, along with proprietary spark recognition and control algorithms to minimize carbonization, tissue adhesion, and unintended thermal injury.
Literature Review
SC 6
Must consist of compact design with multiple socket configurations (monopolar, bipolar, universal connections) accommodating international and manufacturer-specific instrument standards, wireless and wired footswitch options, and compatibility with smoke evacuation and insufflation systems for streamlined OR workflow.
Literature Review
SC7
Must include a minimum one year manufacturer warranty covering parts and labor, with availability of installation, user training, and ongoing service support programs.
Literature Review


Evaluation Sub-factors
1. Design: Design features and function will be evaluated based on, but not limited to, the following:
Centralized touchscreen user interface: Large, color touchscreen with logical application-oriented men for quick selection and confirmation of modes to include APC settings.
Multi-instrument connectivity and APC integration to include argon probes and APC hand pieces.
Procedure and instrument-based presents: Recognizes instrument and procedure-specific programs that automatically load parameters and standardizes set-up.

2. Performance: Performance capabilities, features and functions of the device offered will be evaluated for technical performance, reliability, and clinical effectiveness. These elements include, but are not limited to:
High dynamic power delivery: Power supply is able to maintain stable output under variable loads and APC modes.
Rapid response measurement rate: High measurement of frequency of target tissue effects across different tissue types and cutting speeds supporting argon-assisted coagulation lines.
Multi-modality support: Concurrent support for monopolar, bipolar, and hybrid/argon-assisted applications across platforms without swapping generators during an on-going procedure.

3. Safety: All features and functions of the equipment shall be evaluated for the ability to be safely installed, secured, and protected against harm; physical or any form. These elements include, but are not limited to:
Regulatory compliance and clearances: FDA 510(K) clearance status.
Systems and operational features safety related to electrical and argon-gas.
Warning and alarms capability

4. Quality/Construction/Training: Elements will include, but are not limited to:
Robust construction and medical-grade standards.
Power consumption, backup power, and energy efficiency.
Terms and conditions of installation, training, and service agreement programs.
Expected life cycle to include sanitation, infection control, and maintenance.
3. PRODUCT REFRESHÂ Â

Product refresh is when a current CLIN is no longer being manufactured due to
obsolescence and the product item is being replaced with a newer, and more often, a
superior version of the same item. The current CLIN product will be revised to reflect the
refreshed product information, manufacturer s part number, IDIQ price (inclusive of
Service Level Agreement (SLA) fee), etc.

The Government reserves the right to not accept the products quoted under
product refresh. The contractor will be notified in writing if a product refresh is not
accepted. All products quoted shall be provided with the warranty that is agreed upon
for this contract.

The contractor agrees to ensure that all upgraded improved/replaced products
meet American with Disabilities Act (ADA) and Health Information Portability and
Accountability Act (HIPAA) Federal requirements.

The contractor shall provide the Contracting Officer s Representative (COR) and Contracting Officer the following information for product refresh:

(1) A list of specific awarded item(s) being refreshed in the Price/Cost Schedule
(to include commercial pricing, discount offered, and IDIQ price (inclusive of SLA
fee));
(2) Product literature for the item(s) refreshed.
(3) A detailed description of the differences or benefits of refreshed as compared
to the item(s) being discontinued or added.
(4) Proper identification of any product requirements and/or procedures related to
those product(s) quoted to be refreshed or upgraded.
(5) FDA approval, if applicable
(6) Provide historical sales to VA by item(s), if applicable
(7) Copy of Commercial Warranty.

The request shall be submitted to the COR for review and recommendation of approval to be submitted to the Contracting Officer. The Contracting Officer shall prepare a bilateral modification for execution.

4. PRODUCT REMOVAL OR RECALL
For any product awarded under this contract removed or recalled by the manufacturer due to defects in the product or potential dangers to patients, or if any required removal or recall is suggested or mandated by a regulatory or official agency, the manufacturer agrees to take following steps immediately:
Notify the Contracting Officer at the Strategic Acquisition Center in writing, by the most expeditious manner possible.
Provide copies of the notification to the Contracting Officer, COR, and Manager at Product Recall Office, all Agencies and VA Facilities who purchased the product, which include, but not limited to the following:
(1) Complete item description and/or identification, order numbers from
customers and the contract number assigned as a result of an issuance on
the solicitation;
(2) Reasons for modifications, removal or recall; and
(3) Necessary instructions for return for credit, replacement or corrective
action.
A copy of the notification will be provided to:
Manager, Product Recall Office
National Center for Patient Safety
Veterans Health Administration
24 Frank Lloyd Wright Drive, Lobby M
Ann Arbor, MI 48106
5. DELIVERY
The Period of Performance will be from date of award for a base of 12-months with four 12-month option periods. Offerors will be required to deliver Electrosurgical Units, Argon-Enhanced Coagulation systems.
to VHA facilities located in the Continental United States (CONUS) and Outside of the Continental United States (OCONUS). Delivery requirements shall be specified under each individual order.
6. DATA RIGHTS

Commercial license agreements may be made a part of this Contract/Order but only if both parties expressly make them an addendum hereto, as permitted by FAR 12.107. If the commercial license agreement is not made an addendum, it shall not apply, govern, be a part of or have any effect whatsoever on the Contract/Order; this includes, but is not limited to, any agreement embedded in the computer software (clickwrap), any agreement that is otherwise delivered with or provided to the Government with the commercial computer software or documentation (shrink-wrap), or any other license agreement otherwise referred to in any document. If a commercial license agreement is made an addendum, only those provisions addressing data rights regarding the Government s use, duplication and disclosure of data (e.g., restricted computer software) are included and made a part of this Contract/Order, and only to the extent that those provisions are not duplicative or inconsistent with Federal law, Federal regulation, the incorporated FAR clauses and the provisions of this Contract/Order; those provisions in the commercial license agreement that do not address data rights regarding the Government s use, duplication and disclosure of data shall not be included or made a part of the Contract/Order. Federal law and regulation including, without limitation, the Contract Disputes Act (41 U.S.C. § 7101 et seq.), the Anti-Deficiency Act (31 U.S.C. § 1341 et seq.), the Competition in Contracting Act (41 U.S.C. § 3301 et seq.), the Prompt Payment Act (31 U.S.C. § 3901 et seq.), Contracts for Data Processing or Maintenance (38 USC § 5725), and FAR clause 52.212-4, 52.227-14 shall supersede, control, and render ineffective any inconsistent, conflicting, or duplicative provision in any commercial license agreement. In the event of conflict between this clause and any provision in the Contract/Order or the commercial license agreement or elsewhere, the terms of this clause shall prevail. The Contractor shall deliver to the Government all data first produced under this Contract/Order with unlimited rights as defined by FAR 52.227-14. Claims of patent or copyright infringement brought against the Government as a party shall be defended by the U.S. Department of Justice (DOJ) IAW 28 U.S.C. § 516; at the discretion of DOJ, the Contractor may be allowed reasonable participation in the defense of the litigation. Any additional changes to the Contract/Order must be made by modification (Standard Form 30) and shall only be made by a warranted Contracting Officer. Nothing in this Contract/Order or any commercial license agreement shall be construed as a waiver of sovereign immunity.Â

ATTACHMENT A - PRICE COST SCHEDULE - NX EQ Electrosurgical Units, Argon-Enhanced Coagulation.
ATTACHMENT B - CONTRACT ADMINISTRATION - NX EQ Electrosurgical Units, Argon-Enhanced Coagulation.
ATTACHMENT C - CONTRACT CLAUSES - NX EQ Electrosurgical Units, Argon-Enhanced Coagulation.
ATTACHMENT D - SOLICITATION PROVISIONS - NX EQ Electrosurgical Units, Argon-Enhanced Coagulation.
ATTACHMENT E REPORTING TOOL - NX EQ Electrosurgical Units, Argon-Enhanced Coagulation.
ATTACHMENT F - PAST PERFORMANCE QUESTIONAIRE - NX EQ Electrosurgical Units, Argon-Enhanced Coagulation.
ATTACHMENT G - PAST PERFORMANCE REFERENCE - NX EQ Electrosurgical Units, Argon-Enhanced Coagulation.

Attachments/Links